toxylact: a06ax02 carbon dioxide producing drugs

The first professional lActological database in the word

Carbon dioxide‑producing rectal drugs (A06AX02) are locally acting gas‑forming laxatives used for short‑term relief of constipation and are considered compatible with breastfeeding because systemic absorption is minimal and class guidance allows use of rectal laxatives in nursing mothers.atcddd.fhi+6

Pharmacotherapeutic group and mechanism

A06AX02 is included in the ATC subgroup A06AX “Other drugs for constipation” and is designated as “carbon dioxide producing drugs.”atcddd.fhi+1
These preparations typically contain inorganic salts such as sodium bicarbonate in combination with acidic agents (e.g. potassium bitartrate) that release carbon dioxide when in contact with rectal moisture, generating gas that mechanically stimulates the rectum and promotes evacuation.pubmed.ncbi.nlm.nih+3

Indications, dosage and administration

Carbon dioxide‑releasing laxatives are indicated for the relief of occasional constipation and lower bowel irregularity, particularly when rapid rectal evacuation is desired or when oral laxatives are unsuitable.webprod.hc-sc+1
They are usually formulated as suppositories or small rectal preparations that are inserted into the rectum, where gas generation occurs within minutes, stimulating defecation; dosing is on an as‑needed basis, often limited to one or two suppositories per episode and short‑term use only.pubmed.ncbi.nlm.nih+2
Because these products act locally and are not intended for chronic systemic therapy, the WHO ATC/DDD Index lists A06AX02 without a defined daily dose.atcddd.fhi

General toxicological profile

The mechanism of action is essentially mechanical: carbon dioxide formation increases local pressure, distends the rectum and triggers defecation reflexes, without significant systemic pharmacological effects when used at recommended doses.pubmed.ncbi.nlm.nih+3
Clinical data suggest that CO₂‑releasing suppositories can be safely employed in the treatment of functional constipation, including in patients at risk of electrolyte disorders, because they do not rely on systemic osmotic or secretory mechanisms.pubmed.ncbi.nlm.nih

Adverse effects are largely local and may include rectal discomfort, bloating, transient cramping, a sensation of gas or urgency, and, rarely, irritation of the anal mucosa. Improper insertion technique or excessive use could theoretically lead to minor mechanical trauma or worsened hemorrhoids. Systemic toxicity is unlikely due to minimal absorption of active components and the very small amount of carbon dioxide produced relative to endogenous intestinal gas or physiological CO₂ levels. Overall, these agents are considered safe when used intermittently and according to product instructions.pubmed.ncbi.nlm.nih+3

Lactation‑toxicology considerations

General specialist guidance on laxatives during breastfeeding states that any laxative can be used during breastfeeding because most are either not absorbed or only minimally absorbed from the gastrointestinal tract, resulting in low or negligible levels in breast milk.sps+1
Rectal preparations such as glycerol and gas‑producing suppositories are specifically mentioned as acceptable options for nursing mothers, with routine infant monitoring beyond normal clinical observation not usually required.sps+1

For carbon dioxide‑producing drugs, systemic exposure in the mother is extremely limited: the active salts act locally and the generated carbon dioxide is predominantly confined to the rectum and lower bowel, with any absorbed fraction being trivial compared with endogenous production. This implies that transfer of the active ingredients or carbon dioxide into breast milk is negligible and clinically insignificant. Consequently, standard lactation references and clinical practice treat gas‑forming rectal laxatives as compatible with breastfeeding, suitable for short‑term use without interruption of nursing.pubmed.ncbi.nlm.nih+4

No specific human pharmacokinetic studies of A06AX02 agents in breast milk have been published, but the combination of local rectal action, minimal systemic absorption and long experience with rectal laxatives supports the conclusion that these products pose very low risk to breastfed infants when used appropriately.

Clinical use in breastfeeding women

In breastfeeding women, constipation management should prioritize lifestyle measures and oral laxatives with well‑established safety profiles in lactation, but rectal preparations can be valuable when rapid relief of lower bowel constipation is necessary.sps+1
Carbon dioxide‑producing suppositories offer a quick, targeted option for occasional constipation episodes, especially in postpartum women who may have difficulty with oral medications or require prompt rectal emptying.pubmed.ncbi.nlm.nih+2

When used in nursing mothers, clinicians can recommend standard dosing without routine infant monitoring beyond usual observation of feeding and stool habits, as systemic exposure is minimal and any transfer into milk is expected to be negligible. As with all laxatives, prolonged or frequent use should be avoided; persistent constipation warrants evaluation for underlying causes and consideration of alternative therapies. Documentation of indication, duration and response is useful in postpartum care, but breastfeeding need not be interrupted around administration of A06AX02 preparations.sps+1

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.